Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Ann Ist Super Sanita ; 56(4): 462-469, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33346172

RESUMO

INTRODUCTION: Turmeric is the common name for the rhizome of Curcuma longa L. In the recent years, food supplements containing turmeric have been marketed and widely used by an increasing number of consumers. Spontaneous reports of suspected adverse reactions to food supplements are collected within the Phytovigilance system. METHODS: An ad hoc multidisciplinary group investigated the suspected cases of hepatotoxicity reported to the Italian Phytovigilance system associated with the assumption of turmeric food supplements with the methodology specific to pharmacovigilance as well as for the evaluation of the quality and safety of food supplements. RESULTS: A cluster of 28 spontaneous reports of acute hepatitis, mostly with cholestasis, associated with turmeric products were sent to the Italian Phytovigilance system in the first six months of 2019. In all cases, except one, the causality assessment was at least possible. The suspected products were collected and analysed for the presence of drugs, heavy metals, aflatoxins, pesticides, synthetic dyes and pyrrolizidine alkaloids. CONCLUSION: On the basis of the results of all the activities performed by multidisciplinary group, regulatory intervention was taken. This study highlights the importance of developing an integrated evaluation approach for the evaluation of the adverse effects associated with the use of food supplements.


Assuntos
Doença Hepática Induzida por Substâncias e Drogas/etiologia , Curcuma/efeitos adversos , Suplementos Nutricionais/efeitos adversos , Extratos Vegetais/efeitos adversos , Adulto , Idoso , Feminino , Humanos , Itália , Masculino , Pessoa de Meia-Idade
2.
J Med Virol ; 67(3): 451-3, 2002 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12116044

RESUMO

Since the early 1990s, several cases of demyelinating diseases were reported in France in association with the vaccination against hepatitis B. A large scientific, regulatory, and public debate took place to reassure the growing concern of the population. The objective of this paper is to examine the decision process undertaken both in France and in Italy; to outline the main findings of the studies conducted before and after the French decision to suspend the vaccination campaign among adolescents; and to describe the contribution of systematic review and causality criteria in the evaluation of the risk-benefit profile of vaccines. Even on the basis of the early findings, which appeared to be compatible with a low increase in the risk associated with the vaccination, it was apparent that the risk-benefit profile was unchanged for newborns, and was essentially unchanged for adolescents and for high-risk adults. The availability of subsequent negative association studies provided further reassurance. It is essential to rely on well-conducted systematic reviews to produce valid and reliable estimates of the risk-benefit profile.


Assuntos
Vacinas contra Hepatite B/efeitos adversos , Vacinas contra Hepatite B/uso terapêutico , Hepatite B/prevenção & controle , Programas de Imunização , Literatura de Revisão como Assunto , França , Humanos , Itália , Esclerose Múltipla/etiologia , Programas Nacionais de Saúde , Medição de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA